Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
Roland R. Griffiths, Wa Richards, Mw Johnson, Ud Mccann, Robert L. Jesse
Journal of Psychopharmacology May 30, 2008 DOI: 10.1177/0269881108094300 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Double-blind study with follow-up Peer reviewed |
|---|---|
| Sample size | 36 |
| Population | Hallucinogen-naïve adults reporting regular participation in religious/spiritual activities |
| Interventions | Psilocybin Methylphenidate |
| Dose | 30 mg/70 kg psilocybin, 40 mg/70 kg methylphenidate |
| Duration | 14-month follow-up |
| Topics | Mysticism Psilocybin Mystical experience |
| Keywords | Clinical psychology Religious experience Attribution Spirituality Hallucinogen Psychotherapist |
| Citations | 883 |
| Key points | Under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences that, at 14-month follow-up, were considered by volunteers to be among the most personally meaningful and spiritually significant of their lives. |
Abstract
Psilocybin has been used for centuries for religious purposes; however, little is known scientifically about its long-term effects. We previously reported the effects of a double-blind study evaluating the psychological effects of a high psilocybin dose. This report presents the 14-month follow-up and examines the relationship of the follow-up results to data obtained at screening and on drug session days. Participants were 36 hallucinogen-naïve adults reporting regular participation in religious/ spiritual activities. Oral psilocybin (30 mg/70 kg) was administered on one of two or three sessions, with methylphenidate (40 mg/70 kg) administered on the other session(s). During sessions, volunteers were encouraged to close their eyes and direct their attention inward. At the 14-month follow-up, 58% and 67%, respectively, of volunteers rated the psilocybin-occasioned experience as being among the five most personally meaningful and among the five most spiritually significant experiences of their lives; 64% indicated that the experience increased well-being or life satisfaction; 58% met criteria for having had a 'complete' mystical experience. Correlation and regression analyses indicated a central role of the mystical experience assessed on the session day in the high ratings of personal meaning and spiritual significance at follow-up. Of the measures of personality, affect, quality of life and spirituality assessed across the study, only a scale measuring mystical experience showed a difference from screening. When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences that, at 14-month follow-up, were considered by volunteers to be among the most personally meaningful and spiritually significant of their lives.
In the evidence
This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.
-
At 14 months, 58% rated the psilocybin experience among the five most personally meaningful and 67% among the five most spiritually significant of their lives, with the session-day mystical experience measure central to these ratings.
Synthesized
-
State of the evidence: Mysticism Supports
At 14-month follow-up, 58% rated the psilocybin experience among the five most personally meaningful and 67% among the five most spiritually significant experiences of their lives, with session-day mystical experience scores central to these ratings.
Synthesized
Comparable studies
Other randomized controlled trials on mystical experience, most cited first.
Citations in the library
Cited by 660
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs Frontiers in Human Neuroscience 2014
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
and 655 more in the library
Cites 16
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
- The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans Pharmacopsychiatry July 1, 1998
- Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose?effect study Psychopharmacology March 1, 2004
and 11 more in the library